非霍奇金淋巴瘤患者血中CD+4 CD+25 T细胞/CD+4 T细胞比率意义初探

  目的 探讨非霍奇金淋巴瘤（NHL）患者外周血中CD+4 CD+25 T细胞／CD+4 T细胞比率的意义。方法 应用流式细胞技术检测15例健康人、41例初诊NHL患者、16例CTOP方案化疗后完全缓解后的NHL患者及25例化疗后未达到完全缓解的患者单位体积内外周血中CD+4 CD+25 T细胞数量和CD+4 T细胞，计算CD+4 CD+25 T细胞占CD+4 T细胞的比率。结果 初诊NHL患者CD+4 CD+25 T细胞／CD+4 T细胞的比率为（7.54±2.31）％，高于健康者的（4.13±1.25）％（P＜0.05）；化疗完全缓解后NHL患者外周血CD+4 CD+25 T细胞／CD+4 T细胞的比率为（6.26±2.28）％，低于初诊化疗前患者的（7.54±2.31％）（P＜0.05）。化疗后未达到完全缓解患者CD+4 CD+25 T细胞／CD+4 T细胞的比率为（7.85±2.12）％，高于化疗后完全缓解的患者的比率（6.26±2.28）％（P＜0.05）。结论 化疗缓解后的NHL患者外周血中CD+4 CD+25 T细胞／CD+4 T细胞的比率较化疗前及化疗未缓解的患者降低，提示CD+4 CD+25 T细胞／CD+4 T细胞的比率可能与NHL患者免疫功能及治疗效果有关。

A primary study on the meaning of CD+4 CD+25 T cells/CD+4 T cells change in blood of NHL patients

Objective To approach the meaning of CD+4 CD+25 T cells/ CD+4 CD+25 T cells in peripheral blood of NHL patients. Methods The peripheral blood of 15 healthy donors, 41 first diagnosed NHL pa－tients, 16 NHL patients who have gotten completed response and 25 NHL patients who haven't gotten com－pleted response after chemotherapy of CTOP scheme were examined by flow cytometry to define the ratio of CD+4 CD+25 T cells to CD+4 T cells. Results Phenotypic studies demonstrated increased frequency of CD+4 CD+25 T cells in peripheral blood of first diagnosed NHL patients （7.54±2.31％）compared with healthy individuals (4.13±1.25 ％) (P < 0.05). The patients who got completed response after chemotherapy of CTOP scheme had decreased frequency（6.26±2.28 ％）compared with the first diagnosed patients（7.54±2.31 ％）（P < 0.05）and the patients who haven't gotten completed response（7.85±2.12 ％）（P < 0.05）. Conclusion There is a low－er ratio of CD+4 CD+25 T cells/CD+4 T cells in peripheral blood of completed response NHL than that in peripheral blood of first diagnosed NHL patients and the patients who haven't gotten completed response. It indicates that the ratio of CD+4 CD+25 T cells/CD+4 T cells is relative to NHL patients' immunity and curative effect.